×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
|
Dashboard
Analyses
Exchange
Gaps
←
Home
/
Wiki
/
Therapeutic: CSF Dynamics and Glymphatic Therapy in CBS/PSP
therapeutic
2,286 words
KG: ent-dise-bfd8f32d
Contents
CSF Dynamics and Glymphatic Therapy in CBS/PSP
💊
Therapeutic Info
Name
ent-dise-bfd8f32d
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Related Hypotheses (30)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.38
Purinergic Signaling Polarization Control
Score: 0.71
Mechanosensitive Ion Channel Reprogramming
Score: 0.70
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.67
Aquaporin-4 Polarization Rescue
Score: 0.73
SASP-Driven Aquaporin-4 Dysregulation
Score: 0.78
Glymphatic System-Enhanced Antibody Clearance Reversal
Score: 0.54
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.92
CYP46A1 Overexpression Gene Therapy
Score: 0.92
Gamma entrainment therapy to restore hippocampal-cortical sy
Score: 0.85
Circadian Glymphatic Entrainment via Targeted Orexin Recepto
Score: 0.84
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.76
Near-infrared light therapy stimulates COX4-dependent mitoch
Score: 0.74
PARP1 Inhibition Therapy
Score: 0.74
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.71
Orexin-Microglia Modulation Therapy
Score: 0.71
TET2-Mediated Demethylation Rejuvenation Therapy
Score: 0.71
Purinergic P2Y12 Inverse Agonist Therapy
Score: 0.70
Lysosomal Calcium Channel Modulation Therapy
Score: 0.70
Complement C1q Mimetic Decoy Therapy
Score: 0.69
Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th
Score: 0.69
Ganglioside Rebalancing Therapy
Score: 0.69
Hypocretin-Neurogenesis Coupling Therapy
Score: 0.69
Lysosomal Positioning Dynamics Modulation
Score: 0.69
R-Loop Resolution Enhancement Therapy
Score: 0.68
SIRT6-NAD+ Axis Enhancement Therapy
Score: 0.67
Arginine Methylation Enhancement Therapy
Score: 0.65
Glial Glycocalyx Remodeling Therapy
Score: 0.65
HCN1-Mediated Resonance Frequency Stabilization Therapy
Score: 0.56
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.74
Show 25 more
Related Analyses (27)
Neuroinflammation and microglial priming in early Alzheimer'
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Extracellular vesicle biomarkers for early AD detection
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · completed
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · completed
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · archived
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · completed
Senescent cell clearance as neurodegeneration therapy
neurodegeneration · archived
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Show 22 more
Related Experiments (30)
FLS Stimulation and Transcriptomic Analysis
exploratory · proposed · Score: 0.95
CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs
clinical · proposed · Score: 0.90
iPSC-derived endothelial cell iron uptake with RLS CSF expos
exploratory · proposed · Score: 0.90
CSF iron content analysis in RLS patients versus controls
clinical · proposed · Score: 0.85
TREM2 Function in Alzheimer's Disease — From Risk Variant to
validation · proposed · Score: 0.45
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40
Biomarker-Guided Sequential Therapy Selection in Alzheimer's
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
Brain Connectivity-Targeted tACS Trial in Early AD
clinical · proposed · Score: 0.40
Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Anti-Tau Immunotherapy Dosing Optimization
clinical · proposed · Score: 0.40
Experiment: Autoimmune Hypothesis Testing in AD
clinical · proposed · Score: 0.40
Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40
Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?
clinical · proposed · Score: 0.40
Blood-Based Biomarker Panel for Early AD Detection
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
tACS Connectivity Trial in Early Alzheimer's
clinical · proposed · Score: 0.40
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
s:** - Test tau spreading in AQP4 knockout vs wild-type mice
falsification · proposed · Score: 0.40
Show 25 more
See Also (15)
BEACoN Study - Biomarker Exploration in Aging, Cognitio
clinical · Pages share 4 hypotheses
Synaptic Therapy Alzheimer's Research Trial (START): A
clinical · Pages share 4 hypotheses
p-Tau Biomarker in Immunoglobulin Light Chain and Trans
biomarker · Pages share 4 hypotheses
Synaptic Biomarkers in Neurodegeneration
biomarker · Pages share 4 hypotheses
Digital Therapeutic Platform for Swallowing and Droolin
clinical_trial · Pages share 4 hypotheses
Phase 3 Study to Compare the Efficacy and Safety of Mas
clinical · Pages share 4 hypotheses
IL-6 (Interleukin-6) in Neurodegeneration
biomarker · Pages share 4 hypotheses
Liquid Biopsy in Neurodegeneration
biomarker · Pages share 4 hypotheses
Metabolomic Biomarkers in Neurodegeneration
biomarker · Pages share 4 hypotheses
Cell-Free DNA Biomarkers in Neurodegeneration
biomarker · Pages share 4 hypotheses
Neuroimaging Biomarkers for Neurodegeneration
biomarker · Pages share 4 hypotheses
Exosomal Biomarkers in Neurodegeneration
biomarker · Pages share 4 hypotheses
Exosomal miR-155 in Neurodegeneration
biomarker · Pages share 4 hypotheses
Utilisation of Health Services and Quality of Life in A
clinical · Pages share 4 hypotheses
Long-term Effects of Hearing Intervention on Brain Heal
clinical · Pages share 4 hypotheses
Show 10 more
Knowledge Graph (2 edges)
therapeutics-cytoskeletal-dynamics-tubulin-targeting-cbs-psp
describes
ent-dise-bfd8f32d
therapeutics-section-156-pet-therapy-animal-assisted-interventions-cbs-psp
describes
ent-dise-bfd8f32d
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)